OBJECTIVE: To determine whether interferon-gamma release assays (IGRAs) improve the identification of HIV-infected individuals who could benefit from latent tuberculosis infection therapy. DESIGN: Systematic review and meta-analysis. METHODS: We searched multiple databases through May 2010 for studies evaluating the performance of the newest commercial IGRAs (QuantiFERON-TB Gold In-Tube [QFT-GIT] and T-SPOT.TB [TSPOT]) in HIV-infected individuals. We assessed the quality of all studies included in the review, summarized results in prespecified subgroups using forest plots, and where appropriate, calculated pooled estimates using random effects models. RESULTS: The search identified 37 studies that included 5736 HIV-infected individuals. In three longitudinal studies, the risk of active tuberculosis was higher in HIV-infected individuals with positive versus negative IGRA results. However, the risk difference was not statistically significant in the two studies that reported IGRA results according to manufacturer-recommended criteria. In persons with active tuberculosis (a surrogate reference standard for latent tuberculosis infection), pooled sensitivity estimates were heterogeneous but higher for TSPOT (72%; 95% confidence interval [CI], 62-81%) than for QFT-GIT (61%; 95% CI, 47-75%) in low-/middle-income countries. However, neither IGRA was consistently more sensitive than the tuberculin skin test in head-to-head comparisons. Although TSPOT appeared to be less affected by immunosuppression than QFT-GIT and the tuberculin skin test, overall, differences among the three tests were small or inconclusive. CONCLUSIONS: Current evidence suggests that IGRAs perform similarly to the tuberculin skin test at identifying HIV-infected individuals with latent tuberculosis infection. Given that both tests have modest predictive value and suboptimal sensitivity, the decision to use either test should be based on country guidelines and resource and logistic considerations.
OBJECTIVE: To determine whether interferon-gamma release assays (IGRAs) improve the identification of HIV-infected individuals who could benefit from latent tuberculosis infection therapy. DESIGN: Systematic review and meta-analysis. METHODS: We searched multiple databases through May 2010 for studies evaluating the performance of the newest commercial IGRAs (QuantiFERON-TB Gold In-Tube [QFT-GIT] and T-SPOT.TB [TSPOT]) in HIV-infected individuals. We assessed the quality of all studies included in the review, summarized results in prespecified subgroups using forest plots, and where appropriate, calculated pooled estimates using random effects models. RESULTS: The search identified 37 studies that included 5736 HIV-infected individuals. In three longitudinal studies, the risk of active tuberculosis was higher in HIV-infected individuals with positive versus negative IGRA results. However, the risk difference was not statistically significant in the two studies that reported IGRA results according to manufacturer-recommended criteria. In persons with active tuberculosis (a surrogate reference standard for latent tuberculosis infection), pooled sensitivity estimates were heterogeneous but higher for TSPOT (72%; 95% confidence interval [CI], 62-81%) than for QFT-GIT (61%; 95% CI, 47-75%) in low-/middle-income countries. However, neither IGRA was consistently more sensitive than the tuberculin skin test in head-to-head comparisons. Although TSPOT appeared to be less affected by immunosuppression than QFT-GIT and the tuberculin skin test, overall, differences among the three tests were small or inconclusive. CONCLUSIONS: Current evidence suggests that IGRAs perform similarly to the tuberculin skin test at identifying HIV-infected individuals with latent tuberculosis infection. Given that both tests have modest predictive value and suboptimal sensitivity, the decision to use either test should be based on country guidelines and resource and logistic considerations.
Authors: María Elvira Balcells; Carlos M Pérez; Leonardo Chanqueo; Martín Lasso; Marcela Villanueva; Mónica Espinoza; Luis Villarroel; Patricia García Journal: Int J Infect Dis Date: 2008-06-04 Impact factor: 3.623
Authors: R S Garfein; R Lozada; L Liu; R Laniado-Laborin; T C Rodwell; R Deiss; J Alvelais; A Catanzaro; P G Chiles; S A Strathdee Journal: Int J Tuberc Lung Dis Date: 2009-05 Impact factor: 2.373
Authors: Jonathan E Golub; Paul Pronyk; Lerato Mohapi; Nkeko Thsabangu; Mosa Moshabela; Helen Struthers; Glenda E Gray; James A McIntyre; Richard E Chaisson; Neil A Martinson Journal: AIDS Date: 2009-03-13 Impact factor: 4.177
Authors: Christoph Stephan; Timo Wolf; Udo Goetsch; Oswald Bellinger; Gabriele Nisius; Gerhard Oremek; Zbigniew Rakus; René Gottschalk; Sonja Stark; Hans-Reinhard Brodt; Schlomo Staszewski Journal: AIDS Date: 2008-11-30 Impact factor: 4.177
Authors: Martine G Aabye; Pernille Ravn; George PrayGod; Kidola Jeremiah; Apolinary Mugomela; Maria Jepsen; Daniel Faurholt; Nyagosya Range; Henrik Friis; John Changalucha; Aase B Andersen Journal: PLoS One Date: 2009-01-19 Impact factor: 3.240
Authors: Sylvia M LaCourse; Lisa M Cranmer; Daniel Matemo; John Kinuthia; Barbra A Richardson; David J Horne; Grace John-Stewart Journal: J Acquir Immune Defic Syndr Date: 2017-05-01 Impact factor: 3.731
Authors: S R Jonnalagadda; E Brown; B Lohman-Payne; D Wamalwa; C Farquhar; G C John-Stewart Journal: Int J Tuberc Lung Dis Date: 2013-12 Impact factor: 2.373
Authors: E Chiappini; A Lo Vecchio; S Garazzino; G L Marseglia; F Bernardi; E Castagnola; P Tomà; D Cirillo; C Russo; C Gabiano; D Ciofi; G Losurdo; M Bocchino; E Tortoli; M Tadolini; A Villani; A Guarino; S Esposito Journal: Eur J Clin Microbiol Infect Dis Date: 2016-01 Impact factor: 3.267
Authors: Sara C Auld; Scott H Lee; Eleanor S Click; Roque Miramontes; Cheryl L Day; Neel R Gandhi; Charles M Heilig Journal: Ann Am Thorac Soc Date: 2016-12
Authors: D I Ling; M Pai; V Davids; L Brunet; L Lenders; R Meldau; G Calligaro; B Allwood; R van Zyl-Smit; J Peter; E Bateman; R Dawson; K Dheda Journal: Eur Respir J Date: 2011-02-24 Impact factor: 16.671
Authors: Sopharat Vat; Marc Ghannoum; Pierre Laflamme; Mario Dugas; Manon Labrecque; Valéry Lavergne Journal: Can J Infect Dis Med Microbiol Date: 2012 Impact factor: 2.471